Your session is about to expire
← Back to Search
Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer
N/A
Waitlist Available
Led By Kathleen M Dungan, MD, MPH
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately following inpatient hospitalization
Awards & highlights
No Placebo-Only Group
Summary
This trial studies if using a continuous glucose monitor (CGM) can improve satisfaction and reduce stress in managing diabetes for patients with poorly controlled type 2 diabetes and active cancer. The CGM provides real-time blood sugar data to help better manage their condition. Continuous glucose monitoring (CGM) systems help patients manage their care with real-time data and have shown benefits in improving blood sugar control and quality of life.
Eligible Conditions
- Diabetes
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from week 1 to week 4
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 1 to week 4
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) survey score
Secondary study objectives
Change in DTSQ scores
Change in Patient Health Questionnaire scores
Change in various measures of control
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Supportive care (CGM)Experimental Treatment3 Interventions
Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,307 Total Patients Enrolled
Kathleen M Dungan, MD, MPHPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
8 Total Patients Enrolled